Cancer Research Technology
Log in Register
Menu

Anti-BCRABL, Recombinant [7c6]

Invented at Queen Mary University of London

Info

Catalogue Number 153261
Applications IF IP WB
Antigen/Gene or Protein Targets BCRABL
Reactivity Human
Relevance Recombinant antibody directed against BCR-ABL oncoprotein.

Background and Research Application
The BCR gene is involved in the 9:22 translocation that generates the Philadelphia chromosome both in chronic myeloid leukaemia (CML) and in a proportion of cases of acute lymphocytic leukaemia (ALL). A 5' bcr sequence becomes fused to an abl sequence (including tyrosine kinase domain sequences) from chromosome 9. This results in the production of a chimeric BCR-ABL oncoprotein with constitutively active tyrosine kinase activity.
This is a recombinant version of anti-BCRABL monoclonal antibody. Anti-BCRABL antibody may be useful for studies of the oncogene and have potential diagnostic and prognostic applications, particularly within leukaemia. This antibody is specific for the SSINEEITPRRQS epitope of BCR (residues 686-696), and as such is able to recognise full-length BCR and the p210 form of the BCR-ABL fusion protein.
Host Mouse
Immunogen Bcr686 thyroglobulin conjugate
Subclass IgG2a
Formulation PBS
Concentration 1mgml-1
Research Area Cancer
Immunogen UniProt ID Q62199
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.

Six products based on this clone:
- Anti-BCR-ABL [7c6], Mouse IgG2a, Kappa
- Anti-BCR-ABL [7c6], Mouse IgG2a, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors
- Anti-BCR-ABL [7c6], Rabbit IgG, Kappa
- Anti-BCR-ABL [7c6], Human IgG1, Kappa
- Anti-BCR-ABL [7c6], Human IgG1, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.
- Anti-BCR-ABL [7c6], Human IgG4-S228P, Kappa

Concentration
1mg/ml as standard

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Original hybridoma first published in: Walker et al. 1987. Nature. 329(6142):851-3. PMID: 3478595.


Add a reference

References: 1 entry

Original hybridoma first published in: Walker et al. 1987. Nature. 329(6142):851-3. PMID: 3478595.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor